Individuals Discontinuing Weight-Loss Injections Gain Back Weight Far More Rapidly Compared to Those on Conventional Diets

Fresh analysis reveals that patients who come off new slimming jabs like semaglutide or tirzepatide tend to recover reduced body mass far faster than those who end traditional lifestyle programs.

Published data in a prominent health publication shows that while obese people often shed a large proportion of their total mass while on the medication, the weight is regained at an average rate of 0.8 kg per month after stopping.

"Individuals purchasing such treatments should be informed of the potential of fast weight regain when the therapy is stopped," cautioned researcher Dr. Susan Jebb.

Such speed of recovery implies a reversion to starting mass within about one and a half years.

Analyzing Approaches

The analysis, which examined 37 of trials involving over 9,000 of participants, compared the effects of these new drugs with conventional dieting.

Researchers emphasize that individuals who shed pounds through lifestyle changes alone typically experience a slower weight regain—approximately 100 grams monthly—post-intervention.

Explaining the Rapid Rebound

Experts believe the mechanism of the jabs explains the amplified weight return.

These medications copy a body's own chemical called GLP-1, which moderates feelings of fullness.

"Long-term administration of the hormone concentrations far above than the body's typical production might result in the system to generate a reduced amount of its endogenous GLP-1, and could lessen responsiveness to its actions," noted Dr. Adam Collins, a nutrition specialist.

"Withdrawal of this GLP-1 'fix' results in hunger is no longer kept in check, making overeating a significant risk."

A Chronic Disease?

Health authorities suggest the jabs for people with weight-linked medical conditions, alongside recommended lifestyle changes.

A number of clinicians argue that, due to the significant potential of weight regain, the treatment should be considered ongoing.

This view is echoed by drug manufacturers, who note that the results "emphasize the chronic character of excess weight," akin to managing conditions like hypertension.

Patient Experiences

Users who have stopped the jabs report a sudden return of appetite.

"I experienced something flipping and I was suddenly ravenous," described one woman.

This challenge is exacerbated if users have not developed sustainable dietary or behavioural modifications during therapy.

Growing Use

Recent estimates indicate that millions of adults in the UK have tried these injections in the last 12 months, with demand remaining high.

• Use is greater among women than men.
• The middle-aged age group shows the highest level of interest.
• A large proportion obtain the drugs through private prescriptions rather than the NHS.

Finally, experts stress that while the jabs are effective agents for shedding pounds, they are not a permanent solution and long-term success hinges on ongoing behavioural support.